Menopause Diagnosis in Women Using Depot Medroxyprogesterone Acetate (DMPA 150 mg IM every 12 weeks)
Menopause is primarily a clinical diagnosis based on the menstrual history. [1] In women using hormonal contraception such as DMPA, menstrual patterns are altered and biochemical confirmation may be needed when menopause status will change management. [1][2]
Core Diagnostic Approach
Menopause is diagnosed by having no period for at least 12 months when not using hormonal contraception. [1] In women using hormonal contraception, menopause identification can be difficult because of altered bleeding patterns, including amenorrhea. [1]
DMPA-Specific Diagnostic Strategy Using FSH Testing
A serum FSH measurement can be used to assess menopausal status in women over 50 years who are amenorrhoeic while using progestogen-only contraception, including DMPA. [2] In women using DMPA, FSH may be suppressed by the medication, so menopause can be present despite non-elevated FSH. [2] The optimum timing for FSH measurement in women using DMPA is immediately before a repeat DMPA dose (i.e., at the end of the dosing interval). [2]
FSH Thresholds for Menopausal Status While on DMPA
A serum FSH level >30 IU/L supports ovarian insufficiency in women using progestogen-only contraception for purposes of menopause-related decision-making. [2] This FSH-based approach is recommended for women aged >50 years who have amenorrhea and wish to stop contraception before age 55. [2]
Timing and Practical Testing Sequence
FSH testing should be performed on the day of assessment just before the next planned DMPA injection to align with the period when DMPA suppression of gonadotropins is least likely. [2] If FSH is in the premenopausal range, continued contraception is recommended with reassessment rather than stopping based on that single value. [2]
Initiation Thresholds for Switching Management from Contraception to Menopause-Targeted Care
For management decisions related to contraception cessation, all women can generally cease contraception at age 55 because spontaneous conception after this age is exceptionally rare. [2] For women aged >50 who want to stop progestogen-only injectable contraception before 55, FSH can be checked during amenorrhea, with management guided by the result (FSH >30 IU/L indicating ovarian insufficiency). [2]
Common Pitfalls to Avoid With DMPA
FSH testing can be misleading during progestogen-only contraception because DMPA can suppress FSH, yielding a non-elevated result despite menopausal status. [2] FSH-based diagnosis is less reliable if testing is not timed to be just before the next DMPA dose. [2]
Menopause Diagnosis Confirmation Without Reliance on Laboratory Tests
In women aged 45 years or over who are not using hormonal contraception, menopause can be identified without laboratory testing by having no period for at least 12 months. [1] Laboratory tests are not routinely required for diagnosis of menopause in most women, even though hormone levels can be discussed when menopause is uncertain. [2]
Key Points Summary for DMPA Users
Menopause diagnosis while using DMPA should be based on menstrual criteria when not using hormonal contraception. [1] When amenorrhea on DMPA prevents menstrual-based diagnosis, serum FSH can be measured in women aged >50 years who desire menopause-related decision support. [2] The FSH sample should be timed immediately before the next DMPA injection, and FSH >30 IU/L supports ovarian insufficiency for menopause-related decisions. [2]